Nkarta, Inc.
(NASDAQ : NKTX)

( )
NKTX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 0.00%245.251.5%$911.70m
MRNAModerna, Inc. 0.65%160.590.0%$895.06m
VRTXVertex Pharmaceuticals, Inc. 0.12%291.521.9%$531.02m
GILDGilead Sciences, Inc. 0.11%62.801.0%$474.53m
NVAXNovavax, Inc. 0.00%63.5475.7%$457.93m
REGNRegeneron Pharmaceuticals, Inc. 0.00%594.902.6%$439.27m
ILMNIllumina, Inc. 1.38%198.083.3%$364.67m
SNSSSunesis Pharmaceuticals, Inc. 0.00%3.790.7%$264.93m
BIIBBiogen, Inc. 0.47%216.991.8%$251.90m
BNTXBioNTech SE 0.15%160.440.0%$215.62m
CRSPCRISPR Therapeutics AG 0.34%72.950.6%$212.16m
BMRNBioMarin Pharmaceutical, Inc. 0.00%86.414.2%$116.69m
AXSMAxsome Therapeutics, Inc. 2.20%43.681.8%$106.66m
NTLAIntellia Therapeutics, Inc. 2.46%62.002.2%$101.78m
EXASEXACT Sciences Corp. 0.00%43.2917.7%$100.73m

Company Profile

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.